Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02677376 · ClinicalTrials.gov registry record
Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC
A clinical trial, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- 7
- Enrollment target
NCT02677376 is a clinical trial that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 7 participants.
The verdict
NCT02677376 has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- 7 participants
- Enrollment target
Study Summary
To determine the feasibility and success rate of tumor tissue procurement using molecular-image-directed biopsies of responding and non-responding osseous metastases, measured by NaF PET/CT, in patients with metastatic castrate-resistant prostate cancer.
Interventions
- OTHER 18F-Sodium Fluoride (NaF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-06-27 |
| Est. Completion | 2020-01-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02677376
The ClinicalTrials.gov registry entry for NCT02677376 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 18F-Sodium Fluoride (NaF) is the first listed.
NCT02677376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02677376 about?
NCT02677376 is a clinical study titled "Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC". To determine the feasibility and success rate of tumor tissue procurement using molecular-image-directed biopsies of responding and non-responding osseous metastases, measured by NaF PET/CT, in patients with metastatic castrate-resistant prostate cancer.
What is the current status of trial NCT02677376?
This trial is currently completed. The enrollment target is 7 participants. The study started on 2016-06-27. Estimated completion is 2020-01-03.
What interventions are being tested in trial NCT02677376?
The interventions under investigation include: 18F-Sodium Fluoride (NaF) (OTHER).
Who is sponsoring clinical trial NCT02677376?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.